Phase 3 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with stage II, III, or IV ovarian cancer (specifically the epithelial type) whose cancer can be surgically removed, and who are able to provide a tumour tissue sample taken within the last six months (subject to organiser approval)
- People aged between 18 and 70 years old
- People whose overall health and physical functioning is rated as fully active or capable of light activity (ECOG score of 0 or 1)
- People whose blood test results meet specific healthy ranges for white blood cells, red blood cells, platelets, liver function, and kidney function
- People whose estimated life expectancy is at least 3 months
- People whose post-surgery blood test (ctDNA MRD test) shows a positive result, while routine blood tests and imaging scans show no signs of remaining disease
- People who are willing and able to follow the study plan and sign a consent form
Who may not be able to join:
- People who have HIV, hepatitis B, hepatitis C, uncontrolled heart disease, uncontrolled asthma, uncontrolled brain or blood vessel disease, or another condition the trial doctor considers a concern
- People who have previously had a bone marrow or organ transplant
- People with a blood clotting disorder
- People who have active gastrointestinal (gut) bleeding or a known tendency to bleed in the gut
- People with immune deficiency conditions or autoimmune diseases
- People who have received any form of immunotherapy (such as checkpoint inhibitors, therapeutic antibodies, immune cell therapy, or immune system modifiers) within the past month
- People who may have an allergy to immunotherapy treatments
- People whose circumstances — including drug use, or psychological or social factors — may affect their ability to give informed consent or follow the study plan
- Women who are pregnant or breastfeeding
- People who are currently in another clinical trial, or who have participated in one within the past month
- People with any other factor that the trial team believes could affect their safety or ability to take part
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ping Duan, Master, Second Affiliated Hospital of Wenzhou Medical University
Phone: +86 150 6781 0815
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ORR; PFS; OS; CA 125
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.